Home › Psoriatic Arthritis › NCT07111494

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients (age 18 and older) who present to rheumatology clinic
* Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB).
* Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA
* Participants must have a Body Mass Index (BMI) of 30kg/m\^2
* Participants must be treated for PsA in accordance with guidelines
* Have not achieved MDA in PsA patients
* Have a minimum TJC \> 1 and SJC \> at baseline
* Eligible for GLP-1 agonist treatment in accordance with Food Drug Administration (FDA) labeling as determined by the investigator.

Exclusion Criteria:

* Any prior use of GLP-1 agonists
* Inability to provide informed consent
* Current participation in another PsA study
* Treatment initiation by GLP-1 agonists contraindicated by FDA
* Patients with hemoglobin A1c (HbA1c) \> 10 at baseline

About the study

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes.

The main objectives it aims to answer are:

To assess disease outcomes of PsA patients undergoing treatment for concomitant obesity and type 2 diabetes with GLP-1 analogs vs nutrition counseling.

To assess effectiveness as measured by clinical and patient reported outcome measures in patients treated with GLP-1 and nutrition counseling.

Participants will be randomized to receive a GLP-1 or nutrition counseling. Participants will be asked to come to the study center at most four times during a 24-week period. During this time participants will be asked to fill out questionnaires, receive a physical exam, and have their blood drawn.

What is being tested

• GLP-1 agonists (drug)
• Nutrition Counseling (other)

Sponsor: Medical College of Wisconsin · Participants: 22 · Started: May 1, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07111494

Locations in the U.S.

Conditions

• Psoriatic Arthritis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.